Sertraline for the treatment of depression in Alzheimer disease: week-24 outcomes. - Wikidata - wikimedia - TriplyDB

Sertraline for the treatment of depression in Alzheimer disease: week-24 outcomes.

Sertraline for the treatment of depression in Alzheimer disease: week-24 outcomes.

http://www.wikidata.org/entity/Q33539531

about

Dementia Tau-targeted treatment strategies in Alzheimer's disease Cotinine halts the advance of Alzheimer's disease-like pathology and associated depressive-like behavior in Tg6799 mice Cognitive outcomes after sertaline treatment in patients with depression of Alzheimer disease The effect of treatment with selective serotonin reuptake inhibitors in comparison to placebo in the progression of dementia: a systematic review and meta-analysis.Symptomatic and nonamyloid/tau based pharmacologic treatment for Alzheimer disease.Neuropsychiatric symptoms in Alzheimer's disease The development and testing of the quality use of medications in dementia (QUM-D): a tool for quality prescribing for behavioral and psychological symptoms of dementia (BPSD).Depression and risk of developing dementia Antidepressant prescribing patterns in the nursing home: second-generation issues revisited.Citalopram for agitation in Alzheimer's disease: design and methods.Do treatment effects vary among differing baseline depression criteria in depression in Alzheimer's disease study ± 2 (DIADS-2)?The association of psychotropic medication use with the cognitive, functional, and neuropsychiatric trajectory of Alzheimer's disease.Sertraline for the treatment of depression in Alzheimer disease: genetic influences.Population pharmacokinetic modeling of sertraline treatment in patients with Alzheimer disease: the DIADS-2 study.Molecular imaging of neuropsychiatric symptoms in Alzheimer's and Parkinson's disease.Pharmacotherapeutic management of dementia across settings of care.Vascular risk factors and neuropsychiatric symptoms in Alzheimer's disease: the Cache County Study.Is sertraline treatment or depression remission in depressed Alzheimer patients associated with improved caregiver well being? Depression in Alzheimer's Disease Study 2 Depression in cognitive impairment.Physical exercise alleviates debilities of normal aging and Alzheimer's disease.World Federation of Societies of Biological Psychiatry (WFSBP) guidelines for the biological treatment of Alzheimer's disease and other dementias.Efficacy and tolerability of antidepressants in the treatment of behavioral and psychological symptoms of dementia, a literature review of evidence.Effect of selective serotonin reuptake inhibitors in Alzheimer's disease with comorbid depression: a meta-analysis of depression and cognitive outcomes.Systematic review of non-pharmacologic interventions to delay functional decline in community-dwelling patients with dementia.Phenomenology of Depression in Alzheimer's Disease.A Review of Pharmacological Treatments for Depression in Alzheimer's Disease.Update on SSRI Treatment for Neuropsychiatric Symptoms of Dementia.Serotonergic drugs for the treatment of neuropsychiatric symptoms in dementia.What is the therapeutic value of antidepressants in dementia? A narrative review.Herbal medicine for management of the behavioural and psychological symptoms of dementia (BPSD): A systematic review and meta-analysis.[Therapy for patients with dementia. Treatment strategies in the elderly].Patterns of psychotropic prescribing and polypharmacy in older hospitalized patients in Ireland: the influence of dementia on prescribing.Depressive symptoms, antidepressant use, and future cognitive health in postmenopausal women: the Women's Health Initiative Memory Study.Treatment of Alzheimer's disease in Brazil: II. Behavioral and psychological symptoms of dementia.Efficacy of pain treatment on mood syndrome in patients with dementia: a randomized clinical trial.Cognitive and neuropsychiatric impairments in Alzheimer's disease: current treatment strategies.Depressive symptoms in Alzheimer's disease and lewy body dementia: a one-year follow-up study.[Antidepressants for treatment of depression in palliative patients : a systematic literature review].Depression in Alzheimer's disease: consequence or contributing factor?

P2860

Q26860881-CC562812-8B32-4B7E-9224-26491A220F76 Q27023429-4EB93339-8FE2-461E-8624-F8C12FEBCC39 Q33938047-DBC260B4-8AD0-462E-BCB7-6956A3D5184B Q34303563-FDFAFEAF-E61A-45BC-84BE-0139C5CE297B Q34521244-180A2121-601B-4C87-A0B6-4D533E96AF34 Q35765716-39EAA984-C152-4466-A78B-9B68A5FFAC40 Q35823575-832AC3F2-E677-4217-83DD-EA267C7FD9B8 Q35848943-EC732B08-B570-4A31-8EEC-318B876D9BC7 Q35891902-F489ED6B-F2A5-4C81-9E71-C48D0CA8C3C5 Q35903889-F6E4938E-0859-4A90-BB57-9A7707354808 Q35905635-E612DC32-15F1-4125-BA98-8722B8095494 Q36148756-429FA24D-BC67-4B27-BA4A-A736D5E0EC12 Q36252668-099CD7D2-FC98-4EBF-84B4-3E6D835DF782 Q36503660-711320FC-7C68-4F4C-82D1-A7E44EA2BE62 Q36704193-AE977F0D-A61D-4520-88CA-9AFDD5B87CB5 Q36724965-8F263E5E-60D7-4EDC-AD87-3DCA85EE0796 Q36849968-E3BB7990-E991-4451-BE07-6AA24BF3B538 Q37445941-D011030F-D4E5-459D-AA4C-5AF636924B1D Q37543468-0565771C-3345-40DE-BA85-3036EB3BCF9F Q37608839-C8229FA2-5788-4C6A-8FCA-9D58EA9892A4 Q37794278-05308667-4DAD-43CD-8C88-29D78ED805D8 Q37834619-29C26742-BE2B-44DC-BECF-89267D1DF915 Q37856572-0EF55F26-7A7C-4A0D-A84E-D7AEEF05A87C Q38053311-78C1839B-7223-4927-8513-C93B34931EB9 Q38101072-E61886EE-0D73-49C2-983B-5CF7DA8ECE33 Q38592071-8AB69A39-06B3-48CC-B2AE-8D6BD170482A Q38592128-19343A35-230B-4F6F-A991-A621E14AC2DE Q38701753-28731F22-A04F-4D08-B70C-EAC877C15C11 Q38737187-04615983-4C05-491E-ABF9-C2209B6104EC Q38946127-750F161F-3918-4D10-88BC-861F59F5BC8E Q39023920-4573C2C8-B670-45EF-805D-6351A3EBC54D Q39204895-11831B52-D151-4BBA-99AD-06F94304E6A0 Q39487718-DFF87134-34DC-44BF-B98A-C5F839762AA3 Q39657169-6341E005-C54C-4B63-B6CD-8955C73E9A91 Q47141950-50472AF3-BDB8-4426-AF1C-2B8BD8B50B8F Q48108390-7E96AB42-2966-45F1-8C39-C08BAE5C440E Q48254545-DA91FB96-9656-4C73-9504-094A4F8D7C6E Q50783939-21C713AA-5D6F-48C6-AE7D-C42909BF2E71 Q52886915-9C86CB69-7C66-44DF-9AA1-1B7B7A699F9B Q53323044-D790260B-598E-4FBD-B0BE-DA0B4BF60751

P2860

Sertraline for the treatment of depression in Alzheimer disease: week-24 outcomes.

http://www.wikidata.org/entity/Q33539531

description

2010 nî lūn-bûn

@nan

2010 թուականի Ապրիլին հրատարակուած գիտական յօդուած

@hyw

2010 թվականի ապրիլին հրատարակված գիտական հոդված

@hy

2010年の論文

@ja

2010年論文

@yue

2010年論文

@zh-hant

2010年論文

@zh-hk

2010年論文

@zh-mo

2010年論文

@zh-tw

2010年论文

@wuu

name

Sertraline for the treatment of depression in Alzheimer disease: week-24 outcomes.

@ast

Sertraline for the treatment of depression in Alzheimer disease: week-24 outcomes.

@en

Sertraline for the treatment of depression in Alzheimer disease: week-24 outcomes.

@nl

type

label

Sertraline for the treatment of depression in Alzheimer disease: week-24 outcomes.

@ast

Sertraline for the treatment of depression in Alzheimer disease: week-24 outcomes.

@en

Sertraline for the treatment of depression in Alzheimer disease: week-24 outcomes.

@nl

prefLabel

Sertraline for the treatment of depression in Alzheimer disease: week-24 outcomes.

@ast

Sertraline for the treatment of depression in Alzheimer disease: week-24 outcomes.

@en

Sertraline for the treatment of depression in Alzheimer disease: week-24 outcomes.

@nl

P1433

Q33539531-2A19C109-BB91-4248-9C92-2F465D0A12DB

P1476

Q33539531-DBC3FA5C-09BE-465E-990A-41072FF33C14

P2093

Q33539531-14891946-CFF0-4E65-B9E6-AC658C42EE7B

Q33539531-2338F2E1-6459-4166-BE97-F231B093ACE6

Q33539531-2ACAC9E2-163A-47D7-A880-228A9168A49D

Q33539531-33039251-2E35-4C96-A211-C7A8BBAB7571

Q33539531-388907E8-6A51-4C87-8C1E-999BE0044401

Q33539531-3C68B220-D254-4D78-BB45-FF80856B5C6A

Q33539531-78E9E525-1D39-4BE4-87BD-81F526325B7F

Q33539531-983A733E-1CD4-4355-99B2-1D0A92DDB4B2

Q33539531-B967C334-9344-4CBE-A269-133D05C5CCC6

Q33539531-CA92ADAD-EC80-46DE-B920-5750F5F2175E

P2860

Q33539531-2B1149C8-453D-4A01-B7B1-5FE5E74DE3BF

Q33539531-319D2995-3250-48D3-8227-E6CF5617BBE0

Q33539531-3A5CC2A6-9F13-4278-98AE-C29BEE1BF8EF

Q33539531-4BC1541A-0068-40C3-94A0-DA83F1D27A73

Q33539531-535A1F1C-88AA-431B-B73F-6C13F81A3F5D

Q33539531-5FFC5928-8F77-42F3-A1F6-71E9255ABF3D

Q33539531-6284EE77-1B23-4236-9500-294D1E77DF68

Q33539531-62A14F97-FE6F-4E3B-824E-866E54F9C6E5

Q33539531-6949D2E4-E0CA-4989-B0A8-B60C5DD71EEC

Q33539531-6A1E17D9-5B53-4386-B407-E0B2712E0183

P304

Q33539531-BFBB1C67-E723-4297-A5E7-89CA21527885

P31

Q33539531-FD3BAE16-459A-4399-A22F-1592F360C278

P356

Q33539531-0E28849E-FBE9-4BAC-B7D9-9DC756B1559F

P433

Q33539531-EC17D7E1-BAE6-4E22-82C8-F94E111AE82E

P478

Q33539531-F67F3C2E-9D30-46A3-9FDC-6CA705509242

P50

Q33539531-8A5EDDD6-65C7-4719-B595-04277371FE5B

P577

Q33539531-095765B2-E715-4F4F-A597-2E9E0B6CDB5F

P698

Q33539531-D924A767-6BE2-4C7F-8622-D8FCF91286DD

P921

Q33539531-5469F493-F250-460E-B301-1629D9D0FFE4

P932

Q33539531-2FE5494C-DC35-426E-A4AB-09B789C94CC0

P356

JGP.0B013E3181CC0333

P1433

American Journal of Geriatric Psychiatry

P1476

Sertraline for the treatment of depression in Alzheimer disease: week-24 outcomes.

@en

P2093

Anton P Porsteinsson

http://www.w3.org/2001/XMLSchema#string

Barbara K Martin

http://www.w3.org/2001/XMLSchema#string

Constantine Frangakis

http://www.w3.org/2001/XMLSchema#string

Constantine G Lyketsos

http://www.w3.org/2001/XMLSchema#string

Curtis L Meinert

http://www.w3.org/2001/XMLSchema#string

Cynthia A Munro

http://www.w3.org/2001/XMLSchema#string

DIADS-2 Research Group

http://www.w3.org/2001/XMLSchema#string

Daniel Weintraub

http://www.w3.org/2001/XMLSchema#string

Jacobo E Mintzer

http://www.w3.org/2001/XMLSchema#string

Lon S Schneider

http://www.w3.org/2001/XMLSchema#string

P2860

“Mini-mental state”

Point and 5-year period prevalence of neuropsychiatric symptoms in dementia: the Cache County Study.

Comparison of citalopram, perphenazine, and placebo for the acute treatment of psychosis and behavioral disturbances in hospitalized, demented patients.

Provisional diagnostic criteria for depression of Alzheimer disease.

Cornell Scale for Depression in Dementia.

An inventory to assess activities of daily living for clinical trials in Alzheimer's disease. The Alzheimer's Disease Cooperative Study.

Provisional diagnostic criteria for depression of Alzheimer disease: rationale and background.

Efficacy and safety of antidepressants for treatment of depression in Alzheimer's disease: a metaanalysis.

Research consent for cognitively impaired adults: recommendations for institutional review boards and investigators.

Observed association between antidepressant use and pneumonia risk was confounded by comorbidity measures

P304

332-340

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1097/JGP.0B013E3181CC0333

http://www.w3.org/2001/XMLSchema#string

P433

4

http://www.w3.org/2001/XMLSchema#string

P478

18

http://www.w3.org/2001/XMLSchema#string

P50

P577

2010-04-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

20220589

http://www.w3.org/2001/XMLSchema#string

P921

Alzheimer's disease

P932

2849739

http://www.w3.org/2001/XMLSchema#string